Brian O'Connell

More than $1 out of every $9 under professional management in the United States is involved in socially responsible investing.

The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008

Closer examination shows there's a strong bond between the biotech market and the unraveling credit markets.

When you start out, keep your small-cap exposure to no more than 10% of your holdings, and gradually increase.